Sotyktu Tablet, Film Coated
Product Images NDC 0003-0895

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Sotyktu (NDC 0003-0895). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem-structure (Chem Structure)

Chemical structure diagram of deucravacitinib, showing its molecular framework including nitrogen-containing heterocycles and various functional groups as part of the active ingredient. The image is a line drawing typical for illustrating drug molecules.*

FDA Label Image

Deucravacitinib-principal-display-panel-label.jpg (Deucravacitinib Principal Display Panel Label)

Label for SOTYKTU (deucravacitinib) tablets, 6 mg strength, oral use, containing 30 film-coated tablets. The label includes the NDC 0003-0895-11 and is distributed by Bristol Myers Squibb Company, E.R. Squibb & Sons, L.L.C. It features usage instructions and warnings, including 'Rx only.'*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.